LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

480.34 1.05

Buy Sell

Overview

Share price change

24h

Current

Min

462.01

Max

480.49

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+44.5% upside

Dividends
By Dow Jones
Next Earnings	19 lut 2026

Market Stats
By TradingEconomics
Market Cap	1.9B 11B
Previous open	479.29
Previous close	480.34

News Sentiment

By Acuity

15%

85%

15 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lut 2026, 23:47 UTC

Hot Stocks

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 lut 2026, 22:59 UTC

Earnings

Acquisitions, Mergers, Takeovers

Grab Holdings to Buy U.S.-Based Stash Financial

11 lut 2026, 23:54 UTC

Earnings

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 lut 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 lut 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 lut 2026, 23:49 UTC

Earnings

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 lut 2026, 23:45 UTC

Earnings

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 lut 2026, 23:42 UTC

Earnings

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 lut 2026, 23:41 UTC

Earnings

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 lut 2026, 23:40 UTC

Earnings

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 lut 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 lut 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 lut 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 lut 2026, 22:58 UTC

Earnings

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 lut 2026, 22:57 UTC

Earnings

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 lut 2026, 22:54 UTC

Earnings

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 lut 2026, 22:53 UTC

Earnings

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 lut 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 lut 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 lut 2026, 22:23 UTC

Earnings

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 lut 2026, 22:22 UTC

Earnings

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 lut 2026, 22:22 UTC

Earnings

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 lut 2026, 22:19 UTC

Earnings

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 lut 2026, 22:16 UTC

Earnings

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

44.5% upside

12 Months Forecast

Average 705.56 USD 44.5%

High 964 USD

Low 570 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

15 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.